Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q1 2022
Holdings as of Mar 31, 2022, filed May 16, 2022. Long positions only; changes compare share counts with Q4 2021.
- Positions
- 27
- +2 vs. Q4 2021
- Portfolio value
- $447.7M
- +$15.9M (+3.7%) vs. Q4 2021
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| MREOMereo BioPharma Group plc | SPON ADS | 1,954,970 | $2.19M | 0.5% | 00.0% | Unchanged | History |
| BCLS Acquisition CorpG0904B105 | COM CL A | 250,000 | $2.47M | 0.6% | 00.0% | Unchanged | – |
| PMVPPMV Pharmaceuticals, Inc. | COM | 125,000 | $2.60M | 0.6% | 00.0% | Unchanged | History |
| DYNDyne Therapeutics, Inc. | COM | 305,125 | $2.94M | 0.7% | 00.0% | Unchanged | History |
| IVAInventiva S.A. | ADS | 262,658 | $2.99M | 0.7% | 00.0% | Unchanged | History |
| GNCAGenocea Biosciences, Inc. | COM NEW | 3,079,756 | $3.85M | 0.9% | 00.0% | Unchanged | History |
| KALVKalVista Pharmaceuticals, Inc. | COM | 312,553 | $4.61M | 1.0% | 00.0% | Unchanged | History |
| TNYATenaya Therapeutics, Inc. | COM | 513,930 | $6.05M | 1.4% | 00.0% | Unchanged | History |
| PTGXProtagonist Therapeutics, Inc | COM | 331,886 | $7.86M | 1.8% | −473,687−58.8% | Reduced | History |
| CLDXCelldex Therapeutics, Inc. | COM NEW | 241,199 | $8.21M | 1.8% | +241,199 | New | History |
| CELCCelcuity Inc. | COM | 920,464 | $8.61M | 1.9% | 00.0% | Unchanged | History |
| IMUXImmunic, Inc. | COM | 893,013 | $10.1M | 2.3% | +893,013 | New | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 481,094 | $11.7M | 2.6% | 00.0% | Unchanged | History |
| KURAKura Oncology, Inc. | COM | 776,514 | $12.5M | 2.8% | +776,514 | New | History |
| VTGNVistagen Therapeutics, Inc. | COM NEW | 10,097,229 | $12.5M | 2.8% | +1,632,230+19.3% | Added | History |
| STSASatsuma Pharmaceuticals, Inc. | COM | 3,711,286 | $14.1M | 3.1% | 00.0% | Unchanged | History |
| TCDATricida, Inc. | COM | 1,744,570 | $14.3M | 3.2% | +497,527+39.9% | Added | History |
| VRDNViridian Therapeutics, Inc. | COM | 951,339 | $17.6M | 3.9% | +103,656+12.2% | Added | History |
| CBAYCymaBay Therapeutics, Inc. | COM | 5,738,500 | $17.8M | 4.0% | +318,604+5.9% | Added | History |
| COGTCogent Biosciences, Inc. | COM | 3,500,768 | $26.2M | 5.9% | +1,219,453+53.5% | Added | History |
| KPTIKaryopharm Therapeutics Inc. | COM | 3,561,052 | $26.2M | 5.9% | +3,561,052 | New | History |
| CYTKCytokinetics Inc | COM NEW | 854,652 | $31.5M | 7.0% | +150,115+21.3% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 1,202,613 | $36.8M | 8.2% | +112,487+10.3% | Added | History |
| ISEEIVERIC bio, Inc. | COM | 2,214,961 | $37.3M | 8.3% | −1,002,202−31.2% | Reduced | History |
| Bellus Health Inc New07987C204 | COM NEW | 5,637,630 | $38.8M | 8.7% | +2,513,017+80.4% | Added | – |
| ACRSAclaris Therapeutics, Inc. | COM | 2,314,648 | $39.9M | 8.9% | −357,698−13.4% | Reduced | History |
| MRUSMerus N.V. | COM | 1,816,421 | $48.0M | 10.7% | +317,531+21.2% | Added | History |
Sold out since Q4 2021 (2)
Positions held at the end of Q4 2021 that are gone from this filing.